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Abstract
Haematological abnormalities are common during combination antiviral therapy for chronic 
hepatitis C. Although dose reduction or
can adversely affect the efficacy of combination antiviral therapy reducing the likelihood of a 
sustained  viral  response  (SVR).  To  avoid  potentially  diminishing  a  patient’s  chance  of 
response, many physicians have begun using growth factors off
neutropenia in hepatitis C. Haematopoietic growth factors are generally well tolerated and 
they may be useful for managing haematological side effects of anti
patients’ quality of life. To date, the role and benefit of these agents during anti
and their positive impact on SVR have not conclusively determined in the published studies. 
However, the possibility of a benefit to individual outpatients re
approach  is  recommended.  This  review  explores  the  incidence,  clinical  significance,  and 
management  of  anaemia,  neutropenia  and  thrombocytopenia  associated  with  combination 
therapy for HCV infection.
Introduction:  Infection  with  hepatitis  C  virus 
(HCV)  is  an  increasing  epidemic  with  over  180 
million  people  infected  worldwide.
1
most  important  cause  of  chronic  liver  disease  in 
Italy  and  is  found  in  nearly  70%  of  cases  either 
alone or with other factors such as HBV and alcohol 
abuse.
2 Infection with HCV persists in about 75% 
of  cases  and  causes  various  degrees  of  liver
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Haematological abnormalities are common during combination antiviral therapy for chronic 
hepatitis C. Although dose reduction or discontinuation can easily treat these side effects, they 
can adversely affect the efficacy of combination antiviral therapy reducing the likelihood of a 
sustained  viral  response  (SVR).  To  avoid  potentially  diminishing  a  patient’s  chance  of 
physicians have begun using growth factors off-label to manage anaemia and 
neutropenia in hepatitis C. Haematopoietic growth factors are generally well tolerated and 
they may be useful for managing haematological side effects of anti-HCV therapy improving
patients’ quality of life. To date, the role and benefit of these agents during anti
and their positive impact on SVR have not conclusively determined in the published studies. 
However, the possibility of a benefit to individual outpatients remains, and an individualized 
approach  is  recommended.  This  review  explores  the  incidence,  clinical  significance,  and 
management  of  anaemia,  neutropenia  and  thrombocytopenia  associated  with  combination 
Infection  with  hepatitis  C  virus 
(HCV)  is  an  increasing  epidemic  with  over  180 
HCV  is  the 
most  important  cause  of  chronic  liver  disease  in 
Italy  and  is  found  in  nearly  70%  of  cases  either 
alone or with other factors such as HBV and alcohol 
Infection with HCV persists in about 75% 
of  cases  and  causes  various  degrees  of  liver
inflammation  and fibrosis; in time it  may lead to 
cirrhosis and hepatocellular carcinoma.
The  primary  aim  of  anti-
permanent  eradication  of  the  virus  or  a  sustained 
viral  response  thereby  reducing  the  risk  of 
progression  to  end-stage  liv
improving quality of life. A sustained viral response 
(SVR)  is  defined  as  undetectable  plasma  HCV
RNA 6  months after  the end  of  treatment,  which 
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Haematological abnormalities are common during combination antiviral therapy for chronic 
discontinuation can easily treat these side effects, they 
can adversely affect the efficacy of combination antiviral therapy reducing the likelihood of a 
sustained  viral  response  (SVR).  To  avoid  potentially  diminishing  a  patient’s  chance  of 
label to manage anaemia and 
neutropenia in hepatitis C. Haematopoietic growth factors are generally well tolerated and 
HCV therapy improving
patients’ quality of life. To date, the role and benefit of these agents during anti-HCV therapy 
and their positive impact on SVR have not conclusively determined in the published studies. 
mains, and an individualized 
approach  is  recommended.  This  review  explores  the  incidence,  clinical  significance,  and 
management  of  anaemia,  neutropenia  and  thrombocytopenia  associated  with  combination 
inflammation  and fibrosis; in  time it  may lead  to 
cirrhosis and hepatocellular carcinoma.
3-4
-HCV  therapy  is 
permanent  eradication  of  the  virus  or  a  sustained 
viral  response  thereby  reducing  the  risk  of 
stage  liver  disease  and 
improving quality of life. A sustained viral response 
(SVR)  is  defined  as  undetectable  plasma  HCV-
RNA 6  months after the  end  of  treatment,  which Medit J Hemat Infect Dis 2010; 2(1); Open Journal System 
lasts typically 6-12 months. This leads to a long-
term clearance of the virus in 98.3% of patients.
5
The  most  effective  treatment  for  chronic  HCV 
infection at present is the combination of pegylated 
interferon  (PEG-IFN)  α-2a  or  α-2b  and  ribavirin 
(RBV).  Both  drugs  have  a  significant  effect  on 
virological  and  histological  responses  and  this 
combined therapy provides a SVR rate of 40% to 
50% in patients with HCV genotype 1 and of 80% 
in  patients  with  HCV  genotypes  2  or  3  in 
randomized controlled trials.
6-7 In spite of  this, at 
least 50% of patients with genotype 1, which is the 
most frequent genotype in the Western world (60-
90%  of  those  infected),  or  with  other  genotypes 
(e.g.  genotype  4)  do  not  respond  to  this  antiviral 
therapy. The SVR rate decreases dramatically when 
adherence to treatment is not optimal. Data derived 
from clinical trials indicate that compliance during 
treatment  and  the  dose  of  RBV  are  important 
factors  for  achieving  a  SVR,  particularly  among 
“difficult-to-treat”  patients,  such as  those  infected 
with HCV genotype 1 and those with high baseline 
levels  of  HCV-RNA.
8-10 The  challenging  side-
effects  of  both  PEG-IFN  and  RBV  reduce 
adherence to treatment and also result in high rates 
of dose reduction and discontinuance of treatment 
in  clinical  trials  and  in  practice.  Among  the  side 
effects  of  combination  therapy,  hematologic 
abnormalities  such  as  anaemia,  neutropenia  and 
thrombocytopenia  have  been  reported  to  result  in 
dose reductions in almost 40% of the subjects
11 with 
consequent  10-20%  reductions  in  the  virological 
responses achieved.
6-7
Management of haematological side effects of 
antiviral  therapy  for  HCV  infection  can  be  an 
important  strategy  for  maximizing  treatment 
outcomes.  Many  physicians  have  begun  using 
haematopoietic  growth  factors  ‘‘off-label’’  to 
manage haematological side effects in patients with 
chronic hepatitis C. A recent French study reported 
that 46% of clinicians treating HCV infection used 
erythropoietic  agents  and  granulocyte  colony 
stimulating  factor  but  there  was  considerable 
variation  in  the  molecules  and  regimen  used.
12
Unfortunately, no official guidelines currently exist, 
and  many  issues  remain  unresolved.  This  article 
reviews  the  haematological  adverse  effects  of 
antiviral  treatment  for  hepatitis  C  and  the  use  of 
haematopoietic agents as potential adjuvant therapy. 
For this review, a literature search of peer-reviewed 
articles  was  made  in  Medline  database  for  the 
period  between  1991  (FDA  approval  of  epoetin 
alpha) and 2010.
Anaemia
Definition  and  frequency:  The  single  most 
common  adverse  event  of  antiviral  treatment  is 
anaemia.  World  Health  Organization  defines 
anaemia as haemoglobin levels < 13 g/dL in men 
and < 12 g/dL in women. During the first 4 weeks 
of combination treatment, mean haemoglobin levels 
decrease  by  an  average  of  2  to  3  g/dl,  with  an 
impaired  compensatory  reticulocytosis.
6-7,13
Haemoglobin concentrations have been reported to 
decrease to below 12 g/dl (mean decrease 3.7 g/dl) 
in 52% of patients receiving combination treatment 
with  PEG-IFN  α-2a  plus  RBV.
14 Significant 
anaemia  (haemoglobin < 10  g/dL)  has  been 
observed  in  up  to  9-13%  of  patients  receiving 
combination therapy with IFN and RBV.
6 Moderate 
anaemia (haemoglobin < 11 g/dL) may be seen in 
30%.
15 Female gender, age > 60, higher RBV dose 
by  body  weight  (12mg/kg  or  more),  the  rate  of 
haemoglobin reduction at week two, Asian race and 
a reduced creatinine clearance are predictors of the 
development of anaemia with anti-HCV therapy.
16-
17
Pathogenesis:  The  aetiology  of  the  anaemia 
induced by HCV therapy is  multifactorial. It is  a 
“mixed  anaemia”,  in  which  both  haemolysis  and 
bone  marrow  suppression  occur  simultaneously.
18
Clinically,  however,  the  contribution  of  RBV  to 
anaemia during combination treatment overshadows 
the  effects  of  IFN  on  the  bone  marrow.  RBV 
induces  a  dose-dependent  haemolytic  anaemia 
which  is  reversible  within  4-8  weeks  of  drug 
discontinuation.  RBV  achieves  an  extensive 
accumulation  in  erythrocytes subsequent to  active 
unidirectional  transmembraneous  transport.  Its 
activation to RBV triphosphate leads to a marked 
depletion of adenosine triphosphate (ATP). Because 
erythrocytes  lack  enzymes  to  hydrolyze  RBV 
triphosphate,  it  accumulates  in  these  cells.  ATP 
deficiency  impairs  the  antioxidant  defence, 
allowing  oxidative  membrane  damage  to  occur. 
This  leads  to  an  accelerated  extravascular 
haemolysis by the reticulo-endothelial system.
13,19
RBV-independent  haematologic  effects  may 
also occur in HCV patients receiving combination 
treatment.  To  a  lesser  extent,  IFN  contributes  to 
anaemia  by  suppressing  bone  marrow  function
20, 
limiting  erythroid-progenitor-cell  proliferation, 
increasing  apoptosis  of  erythroid  cells,  promoting 
autoimmune  haemolytic  reactions,  reducing  renal 
function  and  impairing  compensatory 
reticulocytosis  to  RBV-related  haemolytic 
anaemia.
18,21 Hence, the combined actions of these 
drugs result in a “mixed” anaemia. Medit J Hemat Infect Dis 2010; 2(1); Open Journal System 
Moreover, the anaemia of chronic diseases can 
be observed in patients with chronic HCV infection. 
Its  pathogenesis  is  complex,  involving  impaired 
iron reutilization, low-grade haemolysis, shortened 
red  blood cell  (RBC)  lifespan,  hyposecretion  of 
erythropoietin (EPO) and tissue hyporesponsiveness 
to EPO. These effects are thought to result from the 
actions  of  inflammatory  cytokines,
22-25 which, 
among  other  effects,  increase  the  production  of 
hepcidin,  an  iron  regulatory  hormone  synthesized 
predominantly  in  the  liver.
26 Hepcidin  induces 
decrease  in  plasma  iron  and  sequestration  by 
macrophages  resulting  in  anaemia  of  chronic 
disease.  Recent  reports  have  shown  inadequate 
hepcidin  expression  in  chronic  hepatitis  C 
facilitating the iron deposition in the liver.
27
A blunted production of EPO complicates the 
pathophysiology of anaemia. EPO is an endogenous 
glycoprotein  hormone  which  is  the  primary 
regulator  of  the  rate  of  erythropoiesis.
28 EPO  is 
regulated at the level of the kidney: when oxygen 
delivery  to  the  kidney  is  suboptimal,  EPO  is 
secreted and moves to its site of action – the bone 
marrow  – where  it  enhances  erythrocyte 
proliferation  and  maturation.  It  binds  to  specific 
receptors on the cell surface of RBC precursors in 
the  bone  marrow,  stimulating  the  formation  of 
enucleated reticulocytes, which rapidly mature into 
RBCs,  causing  an  increase  in  the  circulating  red 
blood  cell  mass.
29 Normally,  a  decrease  in  the 
haemoglobin level is accompanied by an increase in 
the  serum  EPO  level,  which  will  ultimately 
normalize the haemoglobin level.
30 The relationship 
between haemoglobin and EPO is less apparent in 
patients with chronic diseases, such as cancer and 
chronic viral infections. HCV-infected patients who 
were treated with PEG-IFN/RBV appeared to have 
inappropriately low levels of endogenous EPO for 
their degree of anaemia.
31 Although serum levels of 
endogenous EPO increased during the combination 
treatment, the haemoglobin level did not return to 
normal, suggesting that the increase in endogenous 
EPO was not sufficient to fully compensate for the 
degree of anaemia.
32 In addition, even though EPO 
is synthesized primarily in the kidney, other organs, 
such  as  the  liver  and  brain,  also  produce  it.  An 
inadequate  EPO  production  by  HCV-infected 
hepatocytes  in  the  liver  also  may  contribute  to  a 
subnormal  rise  in  EPO.  Thus  the  erythropoietic 
response  in  HCV-infected  patients  appears  to  be 
decreased.
31-32
Effect  of  anaemia  on  Ribavirin  dose  and  SVR: 
RBV-induced anaemia is the main reason for dose 
reduction and discontinuance,
33 adversely affecting 
outcome  since  it  reduces  the  probability  of 
achieving SVR.
11 However, maintaining the  RBV 
dose  is  crucial  to  the  outcome  in  patients  with 
chronic hepatitis C who are treatment naive or who 
did not respond to a previous course of therapy.
34
According  to  a  population  pharmacokinetic  and 
pharmacodynamic  analysis  of  RBV  in  patients 
infected with hepatitis C, higher concentrations of 
RBV  in  whole  blood  after  4  weeks  of  treatment 
were associated with a higher rate of response, and 
the  probability  of  response  increased  with 
increasing  concentration.
35 Clinical  data 
investigating the effects of treatment adherence on 
SVR  in  genotype  1  patients  found  that  patients 
receiving less than 80% of the dose of either PEG-
IFN or RBV for less than 80% of the duration of 
therapy  had  suboptimal  viral  response.
8 Another 
study showed that genotype 1 patients who received 
< 60% of cumulative dose of RBV had significantly 
reduced SVR.
36 More recently, the cumulative RBV 
dose to week 12 has been shown to be significantly 
associated  with  early  viral  response  (EVR)  and 
SVR in genotype 1 patients.
37 Similar data was also 
generated by the IDEAL study, which compared the 
rate of adverse events,  safety profile and SVR of
treatment with  PEG-IFN α-2a or  α-2b plus RBV. 
Increased exposure to RBV was associated with an 
increased likelihood of SVR.
38
Furthermore, anaemia can have negative effects 
on both  cerebral function and quality of  life [39] 
because of it can exacerbate other treatment-related 
side effects such as dyspnoea and fatigue. So it has 
marked adverse effects on compliance to the anti-
HCV treatment.
Management Of Anaemia
Ribavirin dose modification-discontinuation:  The 
standard-of-care  management  for  patients  who 
develop  anaemia  during  HCV  therapy  with 
IFN/RBV is RBV dose reduction by 200 mg/day if 
haemoglobin levels  decreases  to  <  10  g/dL,  and 
drug discontinuation when haemoglobin levels drop 
to  <  8,5  g/dl.  Since  such  intervention  can  have 
adverse implication for SVR rates other alternative 
approaches are required.
Erythropoietic growth  factors Pharmacology: To 
avoid potentially diminishing a patient’s chance of 
response,  many  physicians  have  begun  using 
growth  factors  such  as  recombinant  human 
erythropoietin  (rHuEPO)  off-label  to  manage 
anaemia  in  hepatitis  C  with  the  objective  of 
maintaining the RBV dose.
40 The rHuEPO agents 
are  the  biosintetic  form  of  the  hormone  EPO. Medit J Hemat Infect Dis 2010; 2(1); Open Journal System 
Although there  are  small differences  in  the  sugar 
profile  of  the  endogenous  and  recombinant 
hormones,  their  action  in  the  human  body  is 
identical and all rHuEPO bind and activate the EPO 
receptor.  So  their  administration  stimulates  RBC 
production and  predictably increases haemoglobin 
concentrations; it has also proved to be remarkably 
well  tolerated  and  highly  effective.
41 However, 
because  of  the  time  required  for  erythroid 
progenitors  to  mature  and  be  released  into  the 
circulation,  a  significant  increase  in  haemoglobin 
concentration  does not usually occur for  2 weeks 
and may take up to 6 weeks. 
There are currently three rHuEPO agents on the 
market: epoetin alpha (EPO-α), epoetin beta (EPO-
β)  (in  Europe  only)  and  darbepoetin  alpha,  a 
structurally  different  synthetic  longer-acting 
analogue  of  EPO-α.  They are  approved  for  the 
treatment of anaemia associated with chronic renal 
failure,  cancer,  HIV  infection  and  in  the  surgical 
setting,  to  reduce  allogenic  blood  transfusion.
29,41
EPO-α  and  EPO-β,  both  produced  by  Chinese 
hamster  ovary  cells,  share  the  same  amino  acid 
sequence  as  endogenous  EPO and  have the  same 
physiological  effects. However,  differences  in  the 
manufacturing  process  between  the  two 
glycoproteins  reflect  differences  in  their 
carbohydrate  moieties,
42 which  determine 
differences  in  the  pharmacokinetic  and 
pharmacodynamic properties between these agents. 
In fact, EPO-β has a prolonged half-life following 
subcutaneous administration and seems to induce a 
greater absolute reticulocyte response than EPO-α 
after subcutaneous administration.
43 They have been 
extensively studied in chronic renal disease.
Precautions: Adverse events related to rHuEPO are 
rare and consist of hypertension, headache, reaction 
at injection site, increased numbers of platelets in 
the  blood  and  an  increased  risk  of  thrombosis.
44
Generally, after a doubling of the initial EPO dose, 
a  further  increment  of  the  dose  is  not  advisable 
because  it  increases  the  risk  of  thrombosis. 
However, these data mainly originate from rHuEPO 
employment in cancer patients, who show different 
characteristics of response and have a greater risk of 
thrombosis  than  PEG-IFN/RBV  treated  patients.
45
Patients with chronic HCV infection do not have a 
pro-coagulative  profile  and  need  a  different 
rHuEPO treatment duration. Myocardial infarct and 
cerebrovascular accident are rare complications in 
non-renal  populations and recent studies have not 
shown  HCV treatment patients  to be  at increased 
risk.
46 Moreover,  rHuEPO  has  been  shown  to 
enhance  platelet  reactivity  and  platelet counts  in 
patients  with  alcoholic  cirrhosis,  an  interesting 
feature  during  antiviral  therapy  in 
thrombocytopenic  HCV-positive  patients  with 
cirrhosis.
47 The occurrence of pure red cell aplasia, 
an uncommon disorder associated with the presence 
of anti-EPO antibodies, was recently reported in a 
small number of patients with HCV infection and 
subjects  with  chronic  renal  failure  treated  with 
EPO-α.
48-49
Before starting rHuEPO therapy it is important 
to  rule  out  its  contraindications.  These  include 
uncontrolled hypertension, iron deficiency anaemia 
and  known  hypersensivity  to  mammalian  cell-
derived products of human albumin.
Erythropoietic agents during HCV therap.
EPO-α: Despite of the agents available EPO-α has 
been  the  agent  commonly  used  in  anti-HCV 
treatments, few clinical trials examining its use in 
this  setting  have  appeared  in  the  peer-reviewed 
literature. 
In  an  uncontrolled pilot  study,  18  hepatitis  C 
patients who developed anemia (haemoglobin < 10 
g/dL or decrease of ≥ 2 g/dL from baseline) during 
antiviral  treatment  were  given  EPO-α  40.000  U 
weekly, and 13 patients also had their RBV dose 
reduced. Epoetin restored 72% of the prior decrease 
in haemoglobin concentration.
50
Dieterich  et  al. randomized  64  HCV-infected 
patients  with  anaemia  (haemoglobin  < 12  g/dL) 
during  combination  PEG-IFN/RBV  therapy  to 
EPO-α  40,000  U/week  s.c.  or  “standard  of  care” 
(SOC)  (dose  reduction/discontinuation, 
transfusion).  Patients  treated  with  EPO-α  had 
significantly higher haemoglobin levels at week 16 
than  the  SOC  group  (13.8  g/dL  vs 11.4  g/dL, 
p<0.001). reductions in RBV dose at week 4 were 
significantly lower in the EPO-α group (p<0.001) 
and,  at  study  end,  83%  of  treatment  group 
maintained  RBV  doses  of  800  mg/day  or  more 
compared with 54% of the SOC group. EPO-α was 
reported to be well tolerated.
51
Afdhal et al. conducted a randomized placebo-
controlled  trial  in  185  HCV-infected  patients  on 
combination  therapy  who  developed  anaemia 
(haemoglobin < 12 g/dL) to investigate the efficacy 
of  EPO-α  in  maintaining  RBV  dose,  improving 
quality of life (QOL) and increasing haemoglobin. 
EPO-α was initiated at 40,000 U/week and titrated 
to 60,000 U weekly if haemoglobin did not increase 
by 1 g/dL after 4 weeks. After 8 weeks, 88% of the 
patients  receiving  epoetin  maintained  RBV  dose 
versus 60%  of  patients  receiving  placebo.  RBV 
dose  did  not  change  significantly  from Medit J Hemat Infect Dis 2010; 2(1); Open Journal System 
randomization to the end of 8 weeks in the EPO-α 
group, whereas a significant decrease in RBV dose 
occurred in the placebo group. Mean haemoglobin 
increased by an average of 2.2 g/dL in the EPO-α 
group compared with only 0.1 g/dL in the placebo 
group (p<0.001). In addition, epoetin significantly 
improved  mean  QOL  scores  and  was  well 
tolerated.
52 A post hoc analysis of this clinical trial, 
however, subsequently reported that QOL scores of 
anaemic  patients  in  the  trial  were  significantly 
lower than those of both the general population and 
patients who had untreated chronic HCV infection, 
diabetes mellitus and congestive heart failure.
53
Although  the  use  of  EPO-α  can  reduce  the 
incidence and severity of anaemia induced by PEG-
IFN and RBV, data about its effects on SVR are 
very  limited.  Only  one  prospective,  randomized, 
controlled trial has evaluated the effect of EPO-α on 
virologic  response  and  SVR.  Shiffman  et  al.
randomized  150  treatment-naïve  patients  with 
chronic HCV genotype 1 into 3 treatment groups: 
(1)  PEG-IFN  plus  weight-based  RBV  (13.3 
mg/kg/day); (2) PEG-IFN plus weight-based RBV 
plus EPO-α 40,000 U/week; or (3) PEG-IFN plus 
higher  dose  weight-based  RBV  (15.2  mg/kg/day) 
plus EPO-α. Epoetin was  initiated at the onset of 
therapy  to  maintain  the  haemoglobin  between  12 
and 15 g/dL and RBV was reduced in decrements of 
200  mg  if  required.  The  incidence  of  RBV  dose 
reduction  was  significantly  reduced  (p<0.05)  and 
the mean dose of RBV received by these patients 
was significantly higher. Declines in haemoglobin 
to less than 10 g/dL were significantly less frequent 
in  group  2  than  group  1  (10%  vs 40%,  p<0.05). 
SVR was similar in group 1 and 2 (19% to 29%) 
whereas  it  was  significantly greater  in  group  3 
patients  (49%,  p<0.05)  who  received  a  higher 
starting  dose  of  RBV,  mostly  by  a  reduction  in 
relapses. The routine use of EPO-α in all patients at 
the start of anti-HCV treatment does not appear to 
be beneficial and failed to enhance SVR given the 
same starting dose of PEG-IFN and RBV. However 
a  higher  dose  of  RBV  at  initiation  of  treatment 
increases SVR by reducing relapse rates.
54
Darbepoetin-α: Darbepoetin is a hyperglycosilated 
protein,  which  gives  it  a  threefold  longer  serum 
half-life, higher in vivo potency, and less-frequent 
dosing  compared  with  EPO-α,  approved  for 
treatment of anaemia associated with chronic renal 
failure and cancer chemotherapy.
55
A  recent  open-label,  phase  II  trial  was 
conducted using darbepoetin-α in 101 patients with 
chronic hepatitis C. Patients received PEG-IFN and 
a  weight-based  dose  of  RBV  (800-1400  mg/day) 
and  patients  who  developed  significant  anaemia 
(haemoglobin < 10.5 g/dL) received darbepoetin-α 
3 μg/kg once every 2 weeks; the dose was titrated to 
achieve a haemoglobin level of 12.0 g/dL. After 81 
days  of  darbepoetin-α,  haemoglobin  significantly 
increased  by  1.9  ±  1.0  g/dL  to  12.1  ±  1.1  g/dL 
(p<0.0001).
56
EPO-β: There  are  limited  data  about  the  use  of 
EPO-β  for  anaemia  of  chronic  HCV  patients 
receiving  combination  therapy.  In  a  retrospective 
cohort  study,  55  chronic  HCV  patients  who 
developed anaemia (haemoglobin  <  10  g/dL)  and 
symptoms  during  antiviral  treatment were  given 
EPO-β 2000 U per visit, and 33 patients also had 
their  RBV  dose  reduced.  A  higher  percentage  of 
patients with RBV maintenance was observed in the 
EPO-β  group  (71%)  compared  with  untreated 
group. The mean haemoglobin change from week 
12 to week 20 was higher in the EPO-β group than 
in untreated group, especially for patients receiving 
a total EPO-β dose of more than 16,000 U (+0.70 
g/dL vs –0.32 g/dL, P=0.023) and of 10,000-14,000 
U (+0.60 g/dL vs –0.32 g/dL, p=0.023). Therefore, 
low  dose of  EPO-β  could maintain  RBV  dose in 
certain  anaemic  HCV-infected  patient  receiving 
combination therapy.
57
Falasca  et  al. randomized  42  HCV-infected 
patients  on  combination  therapy  who  developed 
anaemia (haemoglobin decrease of ≥ 2.5 g/dL from 
baseline) to EPO-β 30,000 U/week s.c. or “standard 
of care” (SOC) (dose reduction/discontinuation), to 
investigate the  effects of  epoetin  on  anaemia  and 
SVR. EPO-β was titrated to 30,000 U twice a week 
if haemoglobin did not increase by 1 g/dL after 4 
weeks. One month after the introduction of EPO-β, 
haemoglobin  was  increased  by  about  1  g/dl 
(p=0.001) in treated group. The viral response at the 
end of treatment was 95.4% in EPO-β group and 
80% in SOC group (p=0.2). SVR was statistically 
higher in EPO-β group than in SOC group (81.8% 
vs 45%, p=0.03). The administration of EPO-β in 
HCV-infected patients receiving combination PEG-
IFN/RBV  treatment  increases  SVR  rates  among 
patients  developing  anaemia  by  means  of  the 
delivery of optimal dosages of RBV and decreased 
discontinuance rates for adverse effects.
58
Whereas  few  studies  have  used  EPO-β,  most 
practitioners  use  EPO-β  because  of  its 
pharmacokinetic  and  pharmacodynamic  properties 
and efficacy. In a French retrospective study on the 
use  of  growth  factors  in  chronic  hepatitis  C 
treatment, EPO-β was the main rHuEPO molecule 
prescribed  in  a  mean  dose  of  30.000  U  weekly 
(range  2.000-80.000  U).
12 Recently,  an  anecdotal Medit J Hemat Infect Dis 2010; 2(1); Open Journal System 
report  has  shown  that  the  use  of  a  high  dose  of 
EPO-β  in  an  HCV-infected  patient  with  severe 
RBV-induced  anaemia  was  well-tolerated  and 
allowed PEG-IFN/RBV treatment to be completed, 
limiting  its  adverse  effects  and  an  optimal  viral 
response to be achieved.
59
Summarizing,  erythropoietic  agents  appear  to 
be  effective  in  increasing  haemoglobin  level, 
allowing  maintenance  of the  RBV  dose  and 
improving the quality of life for the period of time 
they are used. However, their effects on early and 
sustained viral response remain uncertain, as do the 
duration of treatment, optimal dose, and reference 
level of haemoglobin. Identifying patients with pre-
existing  anaemia  and  those  at  high  risk  of 
developing  anaemia  during  anti-HCV  treatment 
facilitates  the  individualisation  of  PEG-IFN/RBV 
therapy with lower RBV dosing or earlier growth 
factor support.
Possible indications for  therapy with  rHuEPO 
include a fall  in  haemoglobin level by >  4  g/dL, 
haemoglobin  levels  of  <  11  g/dL,  and  patients 
developing  symptoms  and  sign  of  anaemia 
(palpitations, dyspnoea, easy fatigability, pallor).
52
If limited hematotoxicity persists despite reducing 
the  RBV  dose  to  10.6  mg/kg/day  (the  minimum 
effective  dose),
6 initiation  of  an  erythropoietic 
growth factor therapy may be considered. The aim 
of  this  treatment  should  be  to  maintain  an 
haemoglobin level of > 11 g/dL and not the return 
to  pre-treatment  levels.
60 The  first  evidence  of  a 
response to rHuEPO administration is an increase in 
the  reticulocyte  counts  within  ten  days.  If  no 
response occurs in 6-8 weeks despite an appropriate 
increase  in  the  dose,  therapy  with  erythropoietic 
growth factors should be discontinued.
60 If the rate 
of  increase  of  haemoglobin  content  with 
erythropoietic agents therapy is > 1 g/dL over two 
weeks, rHuEPO dose should be decreased because 
of  association  with  increased  risk  of 
thromboembolic  phenomena.  Once  an  adequate 
haemoglobin  level  (between  10-12  g/dL)  is 
achieved,  RBV  dose  can  be  increased  to  the 
optimum  level.  Once  started,  adjunct  rHuEPO 
therapy may be required until the end of treatment. 
Disadvantages of these agents are that they adds 
another  parenteral  drug  to  the  patient’s  treatment 
regimen,  thereby  increasing  the  costs, 
inconvenience  and  potential  side-effects.  The 
rHuEPO agents are costly, but when compared with 
standard care, their use has recently been shown to 
be cost-effective in managing HCV, by increasing 
therapeutic  compliance,  improving  the  quality  of 
life and avoiding the complications of chronic liver 
disease.
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Neutropenia
Definition  and  frequency:  Interferon  therapy  is 
associated  with  a  reduction  in  peripheral  white 
blood  cell  counts,  both  neutrophils  and 
lymphocytes. Neutropenia is defined as a peripheral 
absolute  neutrophil  count  below  1.0  x  10
9/L. 
Similar  to  haemoglobin  levels,  neutrophil  counts 
decline rapidly within the first 2 weeks of therapy, 
stabilize  for  the  duration  of  therapy,  and  rapidly 
return  to  baseline  levels  after  treatment 
discontinuation. PEG-IFN result in a greater degree 
of neutropenia than does non pegylated IFN. With 
typical doses of PEG-IFN used in HCV therapy the 
absolute  neutrophil  count  often  decreases  by  30-
50%  from  baseline.  Neutropenia-related  dose 
reductions took place in 24% and 18% of patients 
receiving PEG-IFN α-2a and α-2b, respectively.
11,62-
63
Pathogenesis:  Therapy-related  neutropenia  is 
primarily caused by IFN through direct toxicity to 
the  bone marrow.  Granulocyte  colony  stimulating 
factor  (G-CSF)  is  a  cytokine  produced  by 
monocytes,  macrophages,  endothelial  cells,  and 
fibroblasts in response to such agents as endotoxin, 
TNF, interleukin (IL)-1,  GM-CSF, IL-3, IL-4 and 
IFN-γ.  G-CSF  maintains  basal  neutrophil  counts 
and  generates  neutrophilia  in  response  to 
infections.
64 A negative feedback effect on G-CSF 
may result from long-term IFN use.
62 In the other 
hand,  defective  synthesis  of  endogenous  G-CSF 
during  combination  treatment  may  contribute  to 
neutropenia.
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Effects of neutropenia: Neutropenia is a common 
reason for dose modification or discontinuation of 
PEG-IFN  [6-7].  Usually,  dose  adjustments 
effectively treat this haematologic side effects and 
less than 1% of  patients required permanent drug 
discontinuation. But the resulting suboptimal dosing 
and  potential  impact  on  virologic  response  are 
major  concerns.  Reducing  the  dose  of  PEG-IFN 
can,  like  RBV  dose  reduction,  also  reduce  the 
likelihood of SVR, although this impact has been 
less clearly established.
In the large multicenter study of PEG-IFN α-2b 
and RBV, patients who were randomized to PEG-
IFN 1.5 mg/Kg/week for 1 month followed by 0.5 
mg/kg/week had significantly lower SVR rates than 
did  those  who  received  1.5  mg/kg/week  for  the 
duration of therapy.
6This suggests that maintenance 
of  the  optimal  dose  of  PEG-IFN  for  the  entire Medit J Hemat Infect Dis 2010; 2(1); Open Journal System 
duration of treatment may also be a determinant of 
long-term virologic response. 
Furthermore,  the  clinical  implications  of 
neutropenia  are  less  clear  than  for  anaemia. 
Although neutrophil counts  can fall  to levels that 
have  been  associated  with  an  increased  risk  of 
bacterial  infections  in  oncology  patients,  severe 
infections are uncommon in patients with HCV.
In  a  retrospective  cohort  analysis  factors 
associated with neutropenia and its clinical effects 
during anti-HCV therapy were investigated in 119 
patients. Neutrophil counts changed by an average 
of 34% and stabilized after fourth week of therapy; 
however IFN was not reduced due to neutropenia. 
Bacterial  infections developed in  18%  of  patients 
none  of  which  were  neutropenic.  The  SVR  was 
similar  in  patients  who  developed  significant 
neutropenia compared with those who did not (45% 
vs 42%).
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In  another  retrospective  study,  investigators 
assessed  the severity and  rate of  infection in 209 
patients treated with PEG-IFN plus RBV for 24 or 
48  weeks  depending  on  their  genotype.  Forty-six 
percent  of  patients  developed  neutropenia  with 
absolute neutrophil count < 1500/μL, but reported 
no increased risk of infection.
67
These findings suggest that neutropenia may be 
well  tolerated  by HCV-infected patients  receiving 
combination therapy. This might be explained by a 
temporary enhanced innate immune cells activity. A 
recent  study  demonstrated  that  in  patients  with 
chronic  hepatitis  C  neutrophil  chemotaxis  and 
oxidative  burst  significantly  increased  during 
treatment  and  returned  to  baseline  at  the  end  of 
therapy.
68
Management Of Neutropenia
Interferon  dose  modification-discontinuation: 
Unfortunately,  guidelines  for  adjustment  of  IFN 
relating to neutropenia are unclear with three large 
studies  failing  to  suggest  a  specific  absolute 
neutrophil count values.
6-7,9 The package insert of 
both  PEG-IFN  α-2a  and  α-2b  recommend  dose 
reduction  for  patients  with  neutrophil  counts  less 
than  750  cells/mm
3 and  drug  discontinuation  for 
those  with  counts  less  than  500  cells/mm
3.  The 
minimum effective dose of PEG-IFN appears to be 
1  μg/kg/week.  However,  the  maintenance  of  the 
optimal dose of PEG-IFN for the entire duration of 
treatment may also be a determinant of long-term 
virologic response. The neutrophil count threshold 
used for dose modification was extrapolated from 
data in cancer patients who developed neutropenia 
related to chemotherapy. The implications of these 
data  for  interferon-related  neutropenia  in  patients 
with chronic hepatitis C are not wholly clear.
Granulocyte  colony-stimulating  factor  (G-CSF). 
Pharmacology: G-CSF  is  a  highly  purified,  not 
glycosylated  protein  produced  by  recombinant 
technology in a lab strain of E. coli by the addition 
of a gene expressing the human G-CSF. It induces 
neutrophil  production,  differentiation  and  release 
from  the  bone  marrow.
69 Filgrastim,  lenograstim 
and nartograstim are the recombinant version of G-
CSF commercially available. They are approved for 
use in chemotherapy-induced neutropenia and used 
off-label in HCV therapy. Significant increases in 
the neutrophil counts can be observed within 24 h 
of  G-CSF  administration.  G-CSF  also  appears  to 
cause  selected-end-cell  functional  activation 
including  enhanced  phagocytic  ability.70
Neutrophil levels usually normalize within 1-7 days 
(average four days).
Precautions: In  general  G-CSF  is  well  tolerated. 
Common  side  effects  include  mild-to-moderate 
bone pain secondary to proliferation of neutrophils 
in the bone marrow. Muscle aches, fever, nausea, 
vomiting and local skin reactions may also occur. 
The frequency of bone/muscle pain can be reduced 
by giving G-CSF either two days before or two days 
after  IFN  injection.
71 Rarely,  splenomegaly  and 
spontaneous splenic rupture have also been reported 
with  G-CSF  use.
72-73 Marked  granulocytosis  may 
occur  with  prolonged  therapy.  If  neutropenic 
patients receiving G-CSF develop fever, dyspnoea 
and lung infiltrates, they should be evaluated for the 
possibility  of  adult  respiratory  distress  syndrome 
that warrant immediate cessation of G-CSF therapy 
until the resolution of the symptom.
G-CSF  is  contraindicated  in  patients  with 
known hypersensitivity to E. coli-derived proteins, 
including filgrastim or any of its components.
G-CSF  during  HCV  therapy:  Very  few  studies 
have investigated the use of G-CSF in patients with 
chronic hepatitis C.
Van  Thiel  et  al. evaluated  filgrastim  as  an 
adjunct  to  interferon  in  30 HCV-infected  patients 
with advanced liver disease. They were randomly 
assigned  to  receive  PEG-INF  α-2b  alone  or  with 
300  microg  of  filgrastim  given  twice  a  week. 
Although  the  mean  and  peak  of  white  blood  cell 
counts  were  higher  for  the  patients  receiving 
filgrastim, the nadir values were the same between 
the  two  treatment  groups.  Filgrastim  was  well 
tolerated  and  a  higher  proportion  of  patients Medit J Hemat Infect Dis 2010; 2(1); Open Journal System 
receiving it (53% vs 40%) achieved SVR, but this 
difference was not statistically significant.
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A  retrospective  study  of  132  HCV  patients 
receiving  PEG-IFN  and  RBV  investigated  the 
benefits  of  haematological growth  factors  and  G-
CSF. 17 patients required filgrastim administration 
at  dose  of  30  MU/week.  Following  G-CSF 
administration, neutrophil count improved and the 
optimum  PEG-IFN  dosage  could  be  obtained  or 
restored in 16 (94%) of the 17 patients treated.
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Sharvadze et al. studied 47 patients with HCV 
genotype  1b  infection  treated with  PEG-IFN  plus 
RBV,  41 (87%)  of  whom  developed  neutropenia. 
Neutropenic patients were randomized to filgrastim 
300  μg/week  s.c.  (n=22)  or  PEG-IFN  dose 
reduction/discontinuation (n=19). In all 22 patients 
of  filgrastim  group  the  drug  was  well  tolerated, 
normalized  neutropenia  without  modification  of 
interferon dose and improved quality of life.
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Koirala  et  al. retrospectively  rewieved  163 
patients  who  received  combination  therapy  for 
HCV.  Neutropenia  was  defined  as  absolute 
neutrophil count ≤ 1.0 x 10
9/L and 30 patients was 
treated with G-CSF and matched with a group who 
received  anti-HCV  treatment  without  developing 
neutropenia. G-CSF was given weekly at a dose of 
300 μg giving an average rise in absolute neutrophil 
count of 3.9 x 10
9/L. Eight patients required dose 
escalation,  two  required  dose  reduction  and  one 
stopped  due  to  side  effects  (rash).  There  was  no 
statistically  significant  difference  in  the  SVR 
between the two groups (61% vs 76%, p=0.18).
71
In the study of Younossi et al. conducted in 101 
patients  with  chronic  hepatitis  C,  38%  developed 
neutropenia  with  an  absolute  neutrophil  count  ≤ 
0.75 x 10
9/L and was treated with filgrastim. After 
G-CSF was initiated, patients’ absolute neutrophil 
count increased from 0.75 ± 0.16 x 10
9/L to 8.28 ± 
5.67  x  10
9/L  (p<0.0001).  Adverse  events  of 
filgrastim were predominantly bone pain and body 
aches which occurred in 29% of patients treated and 
splenomegaly was observed in two patients. Finally, 
treatment  with  growth  factors  was  independently 
associated  with  a  SVR  and  55%  (21  of  38)  of 
patients receiving filgrastim therapy achieved SVR 
vs 40% (25 of 63) who did not receive filgrastim 
therapy (p=0.07).
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In a small case series 8 patients with chronic 
HCV-related  hepatitis  who  developed neutropenia 
during  antiviral  treatment  received  lenograstim  at 
the dosage of 263 μg weekly. All patients receiving 
G-CSF  completed  the  antiviral  treatment  with 
standard dose of PEG-IFN, with 75% of patients (6 
of 8) showing a SVR.
77
In a recent retrospective, cross-matched study, 
Koskinas  et  coll.,  232  genotype-1  HCV-infected 
patients were examined. 19 patients who developed 
significant  neutropenia  (neutrophils  <  800/mm
3) 
was treated with a flexibile scheme of 150-300 μg 
of  G-CSF  twice  a  week  and  matched  with  19 
neutropenic  patients  treated  with  IFN  dose 
reduction/discontinuation  as  control  group.  The 
mean decline of the neutrophils was similar in two 
groups  and  nadir  neutrophil  values  were  also  not 
statistically different. A SVR was observed in 32% 
of  patients  treated  with  G-CSF  versus  21%  of 
patients in control group. No side effects related to 
G-CSF was observed.
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Overall,  reasonable  result  have  been  obtained 
when G-CSF has been utilized in some studies to 
avoid IFN dose reductions. G-CSF therapy may be 
considered if neutrophil counts remain < 0.5 x 10
9/L 
despite reducing the PEG-IFN dose to the minimum 
effective level. A suggested dose regimen is starting 
G-CSF therapy at a dose of 300 μg subcutaneously 
once weekly, and then adjusting the dose as per the 
response/requirement.  The  aim  should  be  to 
maintain  a  neutrophil  count  of  ≥  1000  cells/μL 
(return to the pre-treatment levels is not the aim). 
Most patients respond adequately to a G-CSF dose 
of 300 μg/week, but some patients may require up 
to 480 μg filgrastim thrice weekly, whereas others 
may  only  need  150  μg  once  weekly.  Complete 
blood counts should be taken twice or thrice weekly 
to judge the response to therapy. Once an adequate 
neutrophil  count  is  achieved,  IFN  dose  can  be 
increased to the optimal level. Once started, adjunct 
G-CSF therapy may be required until the end of the 
treatment.
Thrombocytopenia
Definition  and  frequency:  A  decrease  in  platelet 
count may be observed in 10-15 % of patients who 
are  receiving  interferon.  Thrombocytopenia  is 
defined  as  a  platelet  count  of  20,000  to  < 
70,000/mm
3 and it is a possible cause of interferon 
dose  reductions  in  less  than  4%  of  patients  on 
combination therapy.
6 It is more severe with PEG-
IFN/RBV  therapy  as  compared  to  non-pegylated 
IFN/RBV  therapy.  It  is  worst  with  PEG-IFN 
monotherapy,
7 suggesting  that  use  of  RBV  may 
blunt the thrombocytopenic effect of interferon as a 
result of reactive thrombocytosis.
With  PEG-IFN,  the  platelet  cont  decreases 
gradually  over  8  week,  stabilizing  thereafter  and 
returning  to  baseline  values  within  4  weeks  of 
stopping therapy. This fall is clinical insignificant in Medit J Hemat Infect Dis 2010; 2(1); Open Journal System 
most  cases  and  bleeding  complication  are 
uncommon.
6-7
In  randomized  clinical trials of  the  PEG-IFN, 
the  rate  of  dose  reduction  attributed  to 
thrombocytopenia  ranged  from  3%  to  6%.
6-7
However thrombocytopenia associated with chronic 
liver disease may prevent initiation of treatment and 
most patients in clinical trials are carefully selected, 
excluding  patients  with  more  advanced  liver 
disease.
Pathogenesis:  Since  thrombocytopenia  has  an 
heterogeneous nature several are the possible cause. 
During anti-HCV combination therapy it is caused 
primarily by a reversible bone marrow suppression 
due to effect of interferon. However, others possible 
mechanisms  may  be  include.  Decreased  platelet 
production occurs,  due  to  decreased  hepatic 
production  of  thrombopoietin  (TPO),  the  major 
regulator  of  both  megakaryopoiesis  and  platelet 
production  in  human  body,
79 and  virus-induced 
bone-marrow  suppression.
80 In  the  other  hand, an 
increased  peripheral  destruction  of  platelets  may 
coexist, both immune-mediated
81 and due to portal 
hypertension  and  hypersplenism  leading  to 
increased  splenic  platelet  sequestration.
82 HCV 
binding  to  platelet  membrane  with  consequent 
binding of anti-HCV antibody and phagocytosis of 
platelets, and derangement of host immune system 
triggering the production of auto-antibodies against 
platelets glycoproteins are the two most frequently 
postulated  immune  mechanisms  explaining 
increased  peripheral  destruction  in  HCV-infected 
cases.
80-81,83
Management of Thrombocytopenia
Current recommendations:  The  usual  protocol 
is to continue with IFN therapy but reduce its dose 
if  the  platelet  count  fails  to  <  30  x  10
9/L,  and 
discontinue  if  it  falls  to  <  20  x  10
9/L.
60 G-CSF 
therapy may be considered if platelet counts remain 
< 30 x 10
9/L in spite of reducing PEG-IFN dose to 
the minimal effective level. 
Actually, the anti-HCV combination therapy to 
eradicate the infection is the most practical strategy 
in treating HCV-related thrombocytopenia.
A  role  for thrombopoietic  growth  factors?
After  the  cessation  of  clinical  trials  of  first 
generation thrombocytopenic growth factors due to 
immunogenicity  issues,  the  introduction  of  non-
immunogenic  second-generation  thrombopoietin 
mimetics  has  opened  a  novel  way  to treat 
thrombocytopenia.
Recently,  an  oral  thrombopoietin-receptor 
agonist, eltrombopag (SB-497115) has been shown 
to  stimulate  megakaryocyte  proliferation  and 
differentiation  and  to  cause  dose-dependent 
increases  in  platelet  counts  in  chimpanzees  and 
humans.
84-86 It appears that eltrombopag binds the 
TPO receptor at a distance from the binding site for 
TPO and appears to initiate signal transduction by a 
mechanism  different  from  thrombocytopenic 
growth  factors  of  first  generation.
87 Thus, 
eltrombopag has an additive, and not competitive, 
effect  on  platelet  production.  It  produces  a  dose-
dependent  increase  in  platelet  proliferation  and 
differentiation  in  chronic  immune 
thrombocytopenic  purpura
88 with  no  rebound 
thrombocytopenia  following  discontinuation 
treatment.
85
In  a  phase  II  study,  eltrombopag  has  been 
shown  to  increase  platelet  counts  in  HCV-related 
cirrhosis. 74 patients with platelet counts of 20-70 x 
10
3/mm
3 were  randomly  assigned  to  receive 
eltrombopag  (30,  50  or  75  mg  daily)  or  placebo 
daily for 4 weeks. At week 4, none of the controls 
had an increase in platelets compared with 75-95% 
of those receiving eltrombopag doses of 30-75 mg 
respectively.  Whereas  only  6%  of  patients  in  the 
placebo  group  completed  the  12  weeks  antiviral 
course, the same was completed by 36%, 53% and 
65%  of  patients  receiving  30,  50  and  75  mg  of 
eltrombopag respectively.
89 Although the study was 
small and thus underpowered, the most commonly 
reported  side  effects  (headache,  dry  mouth, 
abdominal  pain,  and  nausea)  were  of  insufficient 
severity to require discontinuation of the drug.
Eltrombopag  appears  to  be  an  adequate 
candidate  for  the  management  of  HCV-related 
thrombocytopenia.  Despite  the  encouraging  initial 
results,  further  confirmation  of  the  therapeutic 
efficacy  and  safety  of  eltrombopag  in  phase  III 
trials involving standard-duration courses of PEG-
IFN and RBV is required.
Conclusions:  Haematological  abnormalities  are 
common  during  combination  antiviral  therapy  for 
chronic  hepatitis  C.  Although  dose  reduction  or 
discontinuation can  easily treat  these side  effects, 
they  can  adversely  affect  the  efficacy  of 
combination  antiviral  therapy  reducing  the 
likelihood  of  an  SVR.  Haematopoietic  growth 
factors including rHuEPO and G-CSF are generally 
well tolerated and they may be useful for managing 
haematological  side  effects  of  anti-HCV  therapy 
improving patients’ quality of life. However, their 
positive  impact  on  SVR  is  not  substantiated  by 
studies to date. Eltrombopag may allow anti-HCV 
treatment  in  patients  with  thrombocytopenia Medit J Hemat Infect Dis 2010; 2(1); Open Journal System 
although further data are required to validate its true 
indications, dosage, therapeutic efficacy and safety 
profile.  More  studies  are  needed  to  establish  the 
right  dosage  schedule  and  cost-effectiveness  of 
therapy  with  haematopoietic  growth  factors  in 
course of combination antiviral therapy.
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